| 预激方案治疗高危组MDS |
| |
| 引用本文： | 张存业,李厚立.预激方案治疗高危组MDS[J].中国血液流变学杂志,2007,17(4):568-568,572. |
| |
| 作者姓名： | 张存业 李厚立 |
| |
| 作者单位： | 江苏省沛县人民医院,江苏沛县,221600 |
| |
| 摘 要： | 目的预激方案治疗高危组骨髓增生异常综合征(MDS)发病中的疗效。方法对24例高危组MDS进行预激方案治疗,并评价其疗效及不良反应。结果24例MDS患者13例达CR(54.2%),1疗程总有效率58.3%。非血液系统毒副反应较轻,中位粒缺时间6d(0～14d)。结论预激方案治疗高危组MDS疗效可靠,不良反应少,值得探索。
|
| 关 键 词： | 骨髓增生异常综合征 化疗 预激 |
| 文章编号： | 1009-881X（2007）04-0568-01 |
| 收稿时间： | 2007-07-20 |
| 修稿时间： | 2007-07-20 |
Patients with High-risk MDS Treated by Priming Chemotherapy |
| |
| ZHANG Cun-ye,LI Hou-li.Patients with High-risk MDS Treated by Priming Chemotherapy[J].Chinese Journal of Hemorheology,2007,17(4):568-568,572. |
| |
| Authors: | ZHANG Cun-ye LI Hou-li |
| |
| Abstract: | Objective To observe the effect and toxicy of priming chemotherapy in treatment of patients with high-risk myelodysplastic syndromes.Method 23 patients with MDS at RAEB/RAEB-t phase treated by prim-ing chemotherapy.Result 13 cases(54.2%) achieved complete remission and total effective rate was 58.3% for all the patients.The middle duration of neutrophils was 6 days(0~14 days).The treatment relative mortality was 4.3%.Conclusion Priming chemotherapy is an effective and safe treatment for MDS. |
| |
| Keywords: | myelodysplastic syndromes priming chemotherapy |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
|
